Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Olema Pharmaceuticals Inc (NASDAQ: OLMA) was $9.36 for the day, down -2.50% from the previous closing price of $9.6. In other words, the price has decreased by -$2.50 from its previous closing price. On the day, 2.3 million shares were traded. OLMA stock price reached its highest trading level at $9.6 during the session, while it also had its lowest trading level at $8.91.
Ratios:
Our analysis of OLMA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.09 and its Current Ratio is at 11.09. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Guggenheim on October 08, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
On August 12, 2025, Citigroup reiterated its Buy rating and also lowered its target price recommendation from $20 to $21.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $24.Goldman initiated its Buy rating on April 02, 2024, with a $24 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 18 ’25 when Harmon Cyrus sold 10,000 shares for $8.33 per share. The transaction valued at 83,300 led to the insider holds 744,140 shares of the business.
Harmon Cyrus sold 10,000 shares of OLMA for $80,400 on Sep 16 ’25. The Director now owns 754,140 shares after completing the transaction at $8.04 per share. On Sep 18 ’25, another insider, Harmon Cyrus, who serves as the Director of the company, sold 3,086 shares for $8.32 each. As a result, the insider received 25,676 and left with 117,028 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OLMA now has a Market Capitalization of 642417280 and an Enterprise Value of 285259328.
Stock Price History:
The Beta on a monthly basis for OLMA is 2.09, which has changed by -0.2245236 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, OLMA has reached a high of $13.51, while it has fallen to a 52-week low of $2.86. The 50-Day Moving Average of the stock is 19.10%, while the 200-Day Moving Average is calculated to be 69.28%.
Shares Statistics:
OLMA traded an average of 926.87K shares per day over the past three months and 1327830 shares per day over the past ten days. A total of 68.63M shares are outstanding, with a floating share count of 52.86M. Insiders hold about 22.99% of the company’s shares, while institutions hold 85.68% stake in the company. Shares short for OLMA as of 1759190400 were 7791509 with a Short Ratio of 8.41, compared to 1756425600 on 8413141. Therefore, it implies a Short% of Shares Outstanding of 7791509 and a Short% of Float of 12.49.
Earnings Estimates
Currently, 8.0 analysts are dedicated to thoroughly evaluating and rating the performance of Olema Pharmaceuticals Inc (OLMA) in the stock market.The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.4 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.58 and -$2.27 for the fiscal current year, implying an average EPS of -$1.81. EPS for the following year is -$2.0, with 6.0 analysts recommending between -$1.37 and -$2.37.
